Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial Evaluating Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer (GRECCAR - PRODIGE - FRENCH)

NCT03879109 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT03879109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03879109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial Evaluating Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer (GRECCAR - PRODIGE - FRENCH)
Lead sponsor
University Hospital, Bordeaux
Phase
Phase 3
Overall status
Completed
Start date
July 8, 2019
Completion date
February 10, 2026
Enrollment
58 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer